EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Editas Medicine's enterprise value is $162.43 Mil.
Editas Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-163.12 Mil. Therefore, Editas Medicine's EV-to-EBITDA for today is -1.00.
The historical rank and industry rank for Editas Medicine's EV-to-EBITDA or its related term are showing as below:
EDIT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -45.49 Med: -6.4 Max: -0.77
Current: -1
During the past 11 years, the highest EV-to-EBITDA of Editas Medicine was -0.77. The lowest was -45.49. And the median was -6.40.
EDIT's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs EDIT: -1.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), Editas Medicine's stock price is $5.35.
Editas Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.050. Therefore, Editas Medicine's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Editas Medicine EV-to-EBITDA Historical Data
The historical data trend for Editas Medicine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Editas Medicine's EV-to-EBITDA
For the Biotechnology subindustry, Editas Medicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Editas Medicine's EV-to-EBITDA falls into.
Editas Medicine EV-to-EBITDA Calculation
Editas Medicine's EV-to-EBITDA for today is calculated as:
Editas Medicine's current Enterprise Value is $162.43 Mil.
Editas Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-163.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (NAS:EDIT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Editas Medicine's PE Ratio for today is calculated as:
Editas Medicine's share price for today is $5.35.
Editas Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Editas Medicine's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Editas Medicine (Editas Medicine) Business Description
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EDIT has been successfully added to your 